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HGMD and those at the National Center for
Biotechnology Information, European
Bioinformatics Institute and University of
California Santa Cruz. We are pleased to say
that a consortium of members of the
Human Genome Variation Society (www.
hgvs.org) has been responsible for hundreds
of locus-specific mutation database systems
being created, being publicly available and
made use of by HGMD, and this effort will
continue also under the banner of the
Human Variome Project (www.
humanvariomeproject.org).
In conclusion, we congratulate the cura-
tors of HGMD and OMIM for providing
two such crucial resources for inherited
disease diagnostics and research. Our study
raised a number of explicable problems
outlined by Stenson et al, many of which
highlight the problems of the mutation
database field: use of non-standard nomen-
clature, lack of coverage of all types of
variation, lack of annotation of corrections,
and the need for public and private versions
of HGMD due to funding strictures.
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We need a detailed phenome in
the phenomenon of genetics and
congenital heart disease
In their interesting manuscript, Tomita-
Mitchell et al present four novel GATA4
sequence variations as pathogenic substrates
for congenital heart disease (CHD) in
humans.1 CHD is the most common birth
defect and affects almost 1% of all new-
borns. With the substantial improvement in
surgical approaches that has occurred over
the past decades, the number of adults living
with CHD has increased. This fact demands
better insights into the genetics and heredity
of CHD.
The authors identified a variety of synon-
ymous variants with a potential effect on
the translational kinetics of GATA4.
Interestingly, all 18 CHD-associated synon-
ymous sequence variants were exclusively
found in patients with septal or conotruncal
defects (excluding dextro transposition of
the great arteries; D-TGA), which led to the
conclusion that the genetic aetiology of
D-TGA may be different from other con-
otruncal defects. We agree that there is
growing evidence of the functional conse-
quences of ‘‘silent’’ sequence variations in
cardiac diseases. Recently, mRNA analysis of
plakophilin-2 in a patient with a congenital
arrhythmogenic cardiac disease revealed a
cryptic splice site induced by a variant,
which was predicted to be translationally
silent.2 We also reported the GATA4 C274C
variant in two patients with isolated secun-
dum atrial septal defect type II (ASDII),3
supporting conclusion by Tomita-Mitchell et
al of an association of prevalent synon-
ymous variants with congenital septal
defects. Nevertheless, functional studies are
needed to further investigate this important
issue.
Tomita-Mitchell et al presented four CHD
associated GATA4 mutations.1 The large
population screened allowed the authors to
draw conclusion about an overall prevalence
of GATA4 mutations among patients with
sporadic CHD. Combining results from
previous sequencing approaches indicates
that the prevalence of GATA4 mutations is
around 0.4% (2 out of 482) in patients with
sporadic CHD.3–5 The overall rarity of CHD-
associated GATA4 mutations is reinforced
by Tomita-Mitchell et al, who reported four
mutations among 628 subjects with sporadic
CHD (0.6%).1
The A411V variant is, to our knowledge,
the first GATA4 mutation in a patient with
isolated ventricular septal defect. We have
also identified the A411V mutation in a
female patient with cribriform ASDII and
partial anomalous pulmonary venous
return.3 A secundum ASD of the cribriform
type was previously described as a notable
phenotype in a patient with a secundum
ASD due to a mutation in NKX2.5.6
Therefore, it seems likely that cribriform
atrial septal defects have a greater associa-
tion with transcription factor mutations
than do other forms of ASDII, and patients
with this specific phenotype may constitute
interesting screening candidates. Thorough
assessment of minor and more subtle clinical
features may thus help to find common
phenotypes in patients with a genetic CHD.
Consequently, the lack of any medical
features of the index patients and affected
relatives in the paper of Tomita-Mitchell et
al is regrettable.1 Information about specific
phenotypes of mutation carriers is indispen-
sable for dealing with the future challenges
of adults with CHD.
We believe that the vast heterogeneity of
genetics in CHD demands systematic and
detailed phenomic approaches, which may
result in identification of common clinical
features among patients with genetic CHD.
Genotype–phenotype analyses may assist
rapid clarification of the causative gene
mutation and improve our tools for genetic
counselling of patients with hereditary
CHD.
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